[EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) is a key driver in non-small cell lung cancer (NSCLC).
• EGFR ex20ins mutations confer resistance to traditional EGFR-tyrosine kinase inhibitors (EGFR-TKIs).
• Novel targeted therapies are emerging to address this unmet need.

Purpose of the Study:

• To review recent advancements in targeted therapies for EGFR ex20ins mutant NSCLC.
• To assess the efficacy and differences between newly approved and investigational drugs.
• To provide a reference for precision therapy in EGFR ex20ins NSCLC.

Main Methods:

• Literature review of recent clinical trials and research publications.
• Analysis of drug approvals and therapeutic breakthroughs.
• Comparative assessment of novel agents and combination strategies.

Main Results:

• Mobocertinib and Amivantamab are FDA-approved for EGFR ex20ins NSCLC.
• Other agents like Sunvozertinib show promise.
• Combination therapies are also demonstrating efficacy.

Conclusions:

• Emerging targeted therapies offer new hope for overcoming drug resistance in EGFR ex20ins NSCLC.
• Understanding molecular mechanisms and drug differences is crucial for effective treatment selection.
• Multi-pronged therapeutic approaches are vital for improving outcomes in NSCLC patients with EGFR ex20ins.